BioXcel Therapeutics, Inc. (BTAI) fell 19.27 percent to $4.23, losing $.00 on Wednesday, even after announcing that its SERENITY At-Home Phase 3 trial met the primary endpoint for BXCL501, a sublingual film designed to treat agitation in patients with bipolar disorders or schizophrenia outside clinical settings. The company said the data will support a supplemental new drug application for IGALMI in the at-home setting, expected in the first quarter of 2026. The stock opened at $4.92 and traded between $4.24 and $5.19 during the session, compared with a prior close of $5.24 on the Nasdaq. Trading volume spiked to 28.8 million shares, well above the average of 8.4 million. BioXcel shares are trading above their 52-week low of $1.17 but remain far below their 52-week high of $13.36.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.